Moderna Plans to Produce 20 Million Doses of Its COVID-19 Vaccine Candidate in 2020

As the phase 3 clinical trial of Moderna's (NASDAQ:MRNA) COVID-19 vaccine candidate continues, the company on Friday said it expects to produce 20 million doses of it by the end of 2020.